Nothing Special   »   [go: up one dir, main page]

FR2785543B1 - MODIFIED EXOSOMES AND USES - Google Patents

MODIFIED EXOSOMES AND USES

Info

Publication number
FR2785543B1
FR2785543B1 FR9813946A FR9813946A FR2785543B1 FR 2785543 B1 FR2785543 B1 FR 2785543B1 FR 9813946 A FR9813946 A FR 9813946A FR 9813946 A FR9813946 A FR 9813946A FR 2785543 B1 FR2785543 B1 FR 2785543B1
Authority
FR
France
Prior art keywords
modified exosomes
exosomes
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9813946A
Other languages
French (fr)
Other versions
FR2785543A1 (en
Inventor
Christian Bonnerot
Philippe Benaroch
Sebastian Amigorena
Schneider Helene Vincent
Pamela Stumptner
Graca Raposo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9813946A priority Critical patent/FR2785543B1/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CA002349679A priority patent/CA2349679A1/en
Priority to JP2000581168A priority patent/JP2002529074A/en
Priority to AU10514/00A priority patent/AU772451B2/en
Priority to EA200100509A priority patent/EA004428B1/en
Priority to EP99954055A priority patent/EP1127110A1/en
Priority to CN99812879A priority patent/CN1325441A/en
Priority to IL14263499A priority patent/IL142634A0/en
Priority to PCT/FR1999/002691 priority patent/WO2000028001A1/en
Priority to TW088119348A priority patent/TWI224138B/en
Publication of FR2785543A1 publication Critical patent/FR2785543A1/en
Application granted granted Critical
Publication of FR2785543B1 publication Critical patent/FR2785543B1/en
Priority to AU2004203482A priority patent/AU2004203482A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
FR9813946A 1998-11-05 1998-11-05 MODIFIED EXOSOMES AND USES Expired - Fee Related FR2785543B1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9813946A FR2785543B1 (en) 1998-11-05 1998-11-05 MODIFIED EXOSOMES AND USES
PCT/FR1999/002691 WO2000028001A1 (en) 1998-11-05 1999-11-04 Modified exosomes and uses
AU10514/00A AU772451B2 (en) 1998-11-05 1999-11-04 Modified exosomes and uses
EA200100509A EA004428B1 (en) 1998-11-05 1999-11-04 Modified exosomes and uses
EP99954055A EP1127110A1 (en) 1998-11-05 1999-11-04 Modified exosomes and uses
CN99812879A CN1325441A (en) 1998-11-05 1999-11-04 Modified extracellular bodies and uses thereof
CA002349679A CA2349679A1 (en) 1998-11-05 1999-11-04 Modified exosomes and uses
JP2000581168A JP2002529074A (en) 1998-11-05 1999-11-04 Modified exosomes and uses
IL14263499A IL142634A0 (en) 1998-11-05 1999-11-04 Modified exosomes and uses
TW088119348A TWI224138B (en) 1998-11-05 1999-12-16 Membrane vesicles, method for producing the same, composition containing the same, uses thereof, method for producing antibodies and method for detection of the presence of t-lymphocytes specific to antigen-MHC complexes in a biological sample
AU2004203482A AU2004203482A1 (en) 1998-11-05 2004-07-29 Modified exosomes and uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9813946A FR2785543B1 (en) 1998-11-05 1998-11-05 MODIFIED EXOSOMES AND USES

Publications (2)

Publication Number Publication Date
FR2785543A1 FR2785543A1 (en) 2000-05-12
FR2785543B1 true FR2785543B1 (en) 2003-02-28

Family

ID=9532412

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9813946A Expired - Fee Related FR2785543B1 (en) 1998-11-05 1998-11-05 MODIFIED EXOSOMES AND USES

Country Status (10)

Country Link
EP (1) EP1127110A1 (en)
JP (1) JP2002529074A (en)
CN (1) CN1325441A (en)
AU (2) AU772451B2 (en)
CA (1) CA2349679A1 (en)
EA (1) EA004428B1 (en)
FR (1) FR2785543B1 (en)
IL (1) IL142634A0 (en)
TW (1) TWI224138B (en)
WO (1) WO2000028001A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
AU2002331244B2 (en) 2001-08-17 2007-02-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
KR100519384B1 (en) * 2002-08-13 2005-10-06 (주)누백스 Manufacturing method of exosomes using gene transfection and use of the same
CN1313151C (en) * 2002-11-04 2007-05-02 杭州浙大康泰生物技术有限公司 Preparation of high-performance noncellular vaccine and usage
US7914792B2 (en) 2003-02-14 2011-03-29 Exothera L.L.C. Methods and compounds for raising antibodies and for screening antibody repertoires
WO2005094571A1 (en) * 2004-03-31 2005-10-13 Japan Science And Technology Agency Genetically modified hetero animal and method of measuring exocytosis using the animal
WO2006089572A1 (en) * 2005-02-28 2006-08-31 Charité - Universitätsmedizin Berlin Polyelectrolyte capsules for detecting antigen-antibody-reactions
CN1322115C (en) * 2005-07-06 2007-06-20 清华大学 Ectobody loaded with exogenous ligand molecule and its preparation method and application
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CA2676143A1 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
JP5713325B2 (en) 2009-04-17 2015-05-07 アイシス イノヴェイション リミテッド Composition for delivery of genetic material
KR101314868B1 (en) * 2009-07-01 2013-10-08 주식회사이언메딕스 Microvesicles derived from mammalian nucleated cell and use thereof
MX2011013452A (en) * 2009-07-02 2012-04-30 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer.
ES2362589B1 (en) 2009-12-28 2012-05-16 Centre De Recerca En Salut Internacional De Barcelona EXOSOMES DERIVED FROM RETICULOCITS INFECTED WITH PLASMODIUM SP., METHOD FOR OBTAINING AND USE.
JP2015500013A (en) 2011-11-30 2015-01-05 ユニバーシティ オブ ブレーメン MiRNA expression in placental tissue
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2015048844A1 (en) * 2013-10-02 2015-04-09 Xosoma Pty Ltd A method of producing exosomes
EP2862874B1 (en) 2013-10-15 2018-12-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for producing polyclonal antibodies using an antigenic composition comprising protein-containing membrane vesicles
DE102014113688A1 (en) * 2014-09-22 2016-03-24 Jacobs University Bremen Ggmbh ANTIGEN-SPECIFIC IMMUNE COLORING OF T CELLS
US20180042847A1 (en) * 2015-03-16 2018-02-15 Duncan ROSS Method of treatment comprising membrane-enclosed vesicle
EP3302535A1 (en) * 2015-06-03 2018-04-11 Innovex Therapeutics, S.L. Exosomes and their use as vaccine
JP2018520125A (en) 2015-06-10 2018-07-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Use of exosomes for treatment of disease
CA3013685A1 (en) 2016-03-03 2017-09-08 Institut Gustave Roussy Ptps-based vaccines against cancer
US20190112351A1 (en) 2016-04-04 2019-04-18 National Institutes Of Biomedical Innovation, Health And Nutrition Exosome-targeted dna vaccine
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
AU2020315475A1 (en) 2019-07-18 2022-02-03 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN110938670B (en) * 2019-11-07 2023-11-07 南方医科大学南方医院 Application of microbial fluid and serum vesicle reaction in detecting microbial infection
EP4112730A4 (en) * 2020-02-28 2024-10-23 National University Corporation Kanazawa University IMMUNOSUPPRESSION METHOD, AND NUCLEIC ACID COMPOSITION FOR IMMUNOSUPPRESSION AND APPLICATION THEREOF
JP2021000093A (en) * 2020-08-05 2021-01-07 国立研究開発法人医薬基盤・健康・栄養研究所 Exosome-targeted DNA vaccine
EP4537820A1 (en) 2023-10-13 2025-04-16 Institut Gustave-Roussy Compound and combinations comprising said compound to improve immune response
EP4574155A1 (en) 2023-12-22 2025-06-25 Christine Süßmuth Molecules for use in cell regeneration and rejuvenation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635895D1 (en) * 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le ANTIGEN PRESENTING BUBBLES LEAVING FROM CELLS

Also Published As

Publication number Publication date
JP2002529074A (en) 2002-09-10
CN1325441A (en) 2001-12-05
CA2349679A1 (en) 2000-05-18
WO2000028001A1 (en) 2000-05-18
FR2785543A1 (en) 2000-05-12
EA200100509A1 (en) 2001-12-24
EA004428B1 (en) 2004-04-29
AU772451B2 (en) 2004-04-29
TWI224138B (en) 2004-11-21
AU1051400A (en) 2000-05-29
EP1127110A1 (en) 2001-08-29
IL142634A0 (en) 2002-03-10
AU2004203482A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
FR2785543B1 (en) MODIFIED EXOSOMES AND USES
EP0894807A4 (en) GPIb-LIPID COMPLEX AND USES THEREOF
TR199900531A3 (en) Pirazolopyrimidines and pirazolotriazines.
DE69828963D1 (en) WIRSTOFFABGE AND GENTHERAPY SYSTEM
DE19581772T1 (en) Security arrangement
NO20000125L (en) Tiadiazolyl and oxadiazolylphenyloxazolidinone antibacterial agents
LV12624B (en) Thienylazolylalkosietanamines and their application to the drug legusana
ID18010A (en) MODIFIED OLIGOSAKARIDA
BR9506832A (en) N-pyrazolylanilines and n-pyrazolylaminopyridines
FI20000850L (en) Lintel
FR2772599B1 (en) COSMETIC COMPOSITION AND USES THEREOF
DE69918365D1 (en) Connector pair and connector set
DE69916694D1 (en) 2-hydroxy-5-methyl-hexan-3-one and 3-hydroxy-5-methyl-hexan-2-one
FR2772608B1 (en) COSMETIC COMPOSITION AND USES THEREOF
ATE202021T1 (en) FIREPROOF ARRANGEMENTS
FR2778317B1 (en) SWEETENING COMPOSITION AND USES THEREOF
EP1263767A4 (en) NETRINE BETA AND ITS USES
DE69706521D1 (en) MODIFIED INULIN
EP0698666A3 (en) Modified epimorphine
EP0998578A4 (en) SEL-10 AND USES OF SEL-10
FR2778822B1 (en) SWEETENING COMPOSITION AND USES THEREOF
ATA192697A (en) SECURITY FITTING
NO955154D0 (en) Security
EP1299327A4 (en) PHOSPHORY POLYPEPTIDES AND USES THEREOF
FR2802550B1 (en) BIOCUCES, PREPARATION AND USES

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070731